The Technical Analyst
Select Language :

Ovid Therapeutics Inc [OVID]

Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology

Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Ovid Therapeutics Inc is listed at the NASDAQ Exchange

-0.96% $3.11

Last updated: 21 Jan 2022 @ 12:13 pm


FUNDAMENTALS
MarketCap: 211.77 mill
EPS: 1.839
P/E: 1.691
Earnings Date: Mar 14, 2022
SharesOutstanding: 68.09 mill
Avg Daily Volume: 0.213 mill
RATING 2022-01-20
B+
Buy
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/203/204/201/212/213/21
Revenuen/an/an/a
Gr.Profitn/an/an/an/an/a
Ebit
Asset
Debtn/an/an/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.02x
Company: PE 1.691 | sector: PE 82.90
PE RATIO: COMPANY / INDUSTRY
0.00x
Company: PE 1.691 | industry: PE 872.88
DISCOUNTED CASH FLOW VALUE
$4.32
(38.99%) $1.213
Date: 2022-01-21

Insider Trading

Date Person Action Amount type
2021-10-06 Fitzgerald Kevin Joseph Buy 30 000 Stock Option (Right to Buy)
2021-07-14 Rakhit Amit Buy 34 017 Common Stock
2021-07-14 Rakhit Amit Sell 34 017 Common Stock
2021-07-14 Rakhit Amit Buy 34 017 Stock Option (Right to Buy)
2021-07-09 Poole Robert Michael Buy 30 000 Stock Option (Right to Buy)
INSIDER POWER
82.27
Last 94 transactions
Buy: 8 674 562 | Sell: 97 723

Forecast: 13:52 - $3.11

Live Trading Signals (every 1 min)

Forecast 1: 12:22 - $3.13
Forecast 2: 13:12 - $3.12
Forecast 3: 13:52 - $3.11
SCORE
-6.50
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $3.11 (-0.96% )
Volume 0.123 mill
Avg. Vol. 0.213 mill
% of Avg. Vol 57.91 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Ovid Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Ovid Therapeutics Inc

RSI

Intraday RSI14 chart for Ovid Therapeutics Inc

Last 10 Buy & Sell Signals For OVID

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

Date Signal @ Closed %
Jan 21 - 17:03sell$3.13N/AActive
The Live Chart for Ovid Therapeutics Inc
Profile picture for
            Ovid Therapeutics Inc

OVID

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 54 full-time employees. The firm is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

Last 10 Buy Signals
Date Signal @
SEIIJan 21 - 17:05$0.0095
SEACJan 21 - 17:05$1.263
SESNJan 21 - 17:03$0.718
SFSTJan 21 - 17:03$59.50
SANWJan 21 - 17:03$2.44
RNLCJan 21 - 17:03$33.13
RNEMJan 21 - 17:03$49.64
RSLSJan 21 - 17:05$1.390
ROBTJan 21 - 17:03$49.70
RVNCJan 21 - 17:05$13.76

Stock Peers

Company Price Change
OVID3.11-0.96%
ADMS8.220.00%
CABA2.86-4.35%
CHMA3.76-6.00%
CODX7.75-6.18%
GALT1.930-4.93%
IMNM8.06-7.89%
PLXP5.90-4.22%
SRRA18.16-3.64%
TFFP6.50-6.07%
VINC7.002.94%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.